Navigation Links
Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
Date:8/12/2008

EAST SETAUKET, N.Y., Aug. 12 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today that it had filed a patent application for the use of compounds the company is developing for treatment of brain tumors as potential treatments for neurodegenerative diseases including Alzheimer's and Parkinson's Disease.

Dr. John S. Kovach, President and CEO of Lixte, said, "Lixte has developed a series of novel compounds that inhibit the growth of common brain cancers of adults and children in mouse models. We have now found that some variants of these compounds have effects on brain cells that are believed to be potentially useful for the treatment of common neurodegenerative brain diseases. Since Lixte is focused primarily on developing anti-cancer drugs, we are exploring partnerships with companies that have expertise and research programs in the treatment of Alzheimer's Disease."

About Lixte Biotechnology Holdings, Inc.:

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.

Forward-Looking Statements:

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included on Form 10-QSB for the quarter ending June 30, 2008.

Please see our Website: http://www.Lixte.com

For Investor Information, please contact:

Frank Benedetto

Mirador Consulting, Inc. 561-989-3600


'/>"/>
SOURCE Lixte Biotechnology Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
2. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
3. Lixte Biotechnology Holdings, Inc. Announces Completion of Private Placement
4. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
5. Dr. Ari Kiev to be Featured Speaker at Biotechnology Conference Wall Street Unplugged: The Trout Group Investor Seminar in New York July 30
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
7. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
8. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
9. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
10. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
11. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- AfterPill.com is reporting that this week,s Centers for Disease ... who are at risk of unintended pregnancy impacts 43 ... the risks of unprotected sex in particular.  ... the Guttmacher Institute, there are 43 million women in ... have sex without the intention of becoming pregnant.  Despite ...
(Date:2/11/2016)... 11, 2016  Proliant Biologicals is proud to announce ... (BSA) manufacturing facility.  The facility is located on the ... in Feilding. Boone , Iowa.  ... duplicate the systems in the U.S. facility, with critical ... U.S. installations.  --> Boone ...
(Date:2/11/2016)... , Feb. 11, 2016 Brain Cancer ... treatment method at West Cancer Center . ... fields to inhibit cancer cell replication causing death of ... than a decade to show a significant extension in ... (GBM) patients. Currently, West Cancer Center is the only ...
Breaking Medicine Technology:
(Date:2/11/2016)... , ... February 11, 2016 , ... ... for nominations seeking candidates for the Board of Commissioners. Individuals interested in volunteer ... and experience with diversity of clinical practice settings and across allied health to ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in Orange ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:2/11/2016)... ... 11, 2016 , ... Duterte Insurance Group, serving the families ... new charity campaign to raise funds for Ronald McDonald House Charities. On behalf ... . , Ronald McDonald House (RMH) is an internationally renowned nonprofit organization which ...
(Date:2/11/2016)... ... February 11, 2016 , ... Be Well Medical Group (Be ... of Old Town at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well ... medical care in the convenience of their homes, offices or at the practices’ local ...
(Date:2/11/2016)... CO. (PRWEB) , ... February 11, 2016 , ... ... people have become more actively engaged in health and wellness best practices in ... importance of riding this trend. February is American Heart Month, which acts as ...
Breaking Medicine News(10 mins):